The use of biologics in personalized asthma care.
David WatchornFernando HolguinPublished in: Expert review of clinical immunology (2021)
We generally favor omalizumab in the first instance for those severe asthma patients also eligible for other biologics, due to the greater long-term safety data available for this agent. Clinical characteristics predicting response, treatment priorities, and comorbidities must also be considered.